You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors
  1. Alexandra D Frolkis1,
  2. Isabelle A Vallerand2,
  3. Scott B Patten2,3,
  4. Gilaad G Kaplan1,2
  1. 1 Department of Medicine, University of Calgary, Calgary, Alberta, Canada
  2. 2 Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
  3. 3 Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
  1. Correspondence to Dr Gilaad G Kaplan, Medicine and Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada ; ggkaplan{at}ucalgary.ca

https://doi.org/10.1136/gutjnl-2019-318650

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the thoughtful feedback and points raised by authors Moulton, Norton, Powell, Mohamedali and Hopkins regarding the temporality between depression and inflammatory bowel disease (IBD) diagnosis and recommendation to perform further sensitivity analyses.1 The authors correctly highlight that the prodromal effects of IBD, including fatigue and low mood, prior to diagnosis may mimic depression and therefore put temporality into question.2 Furthermore, the median time from Crohn’s disease symptom presentation to diagnosis is 9 months and 75% of patients are diagnosed within 2 years.3 In response, we have performed two sensitivity analyses restricting to observations with at least (1) 9 months between depression and IBD diagnosis and …

    View Full Text

    Footnotes

    • Contributors All authors equally contributed to writing the letter.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests GGK has received honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer and Takeda. He has received research support from Janssen, Abbvie, GlaxoSmith Kline, Merck and Shire. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE AND PBC. UTI Limited Partnership, assignee. Patent 62/555,397. 7 September 2017.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Patient consent for publication Not required.

    Linked Articles